IP Library Granted Patent US 10,113,207
Granted Patent B2
US 10,113,207 · App. 15/495,325 · Granted Oct 30, 2018

Methods and compositions for targeted single-stranded cleavage and targeted integration

Inventor: Jianbin Wang (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
C12Q1/706C12N9/22C12N15/907C12Q1/689C12Q1/708C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,113,207
App. No.
15/495,325
Granted
Oct 30, 2018
Kind
B2
Abstract

Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.

Claims (19)

1. A method of modifying a genomic sequence in a cell, the method comprising introducing a polynucleotide encoding an artificial nuclease into the cell, the artificial nuclease comprising

(i) first and second cleavage domains from an endonuclease, wherein the first cleavage domain is catalytically inactive and the second cleavage domain is catalytically active; and

(ii) a DNA-binding molecule that is heterologous to the first and second cleavage domains, and further wherein the DNA-binding molecule of the nuclease binds to a target sequence in a double-stranded genome and the nuclease induces a site-specific single-stranded break at or near the target sequence in the double-stranded genome such that the genomic sequence is modified.

2. The method of claim 1 , wherein the modification is selected from the group consisting of insertions, deletions and combinations thereof.

3. The method of claim 1 , wherein the genomic sequence comprises a wild-type or mutant sequence.

4. The method of claim 3 , wherein the modification is a point mutation.

5. The method of claim 1 , wherein the modification results in inactivation of an endogenous gene.

6. The method of claim 2 , wherein the modification comprises targeted integration of an exogenous sequence.

7. The method of claim 1 , further comprising providing a second nuclease that makes a second single-stranded break in the genomic sequence.

8. A method of detecting a nucleic acid comprising:

generating a single-stranded break (nick) in a double-stranded DNA of a sample using an artificial nuclease comprising

(i) first and second cleavage domains from an endonuclease, wherein the first cleavage domain is catalytically inactive and the second cleavage domain is catalytically active; and

(ii) a DNA-binding molecule that is heterologous to the first and second cleavage domains, and further wherein the DNA-binding molecule of the nuclease binds to a target sequence in a double-stranded DNA and the nuclease induces a single-stranded break in the double-stranded DNA;

amplifying the nicked DNA; and

detecting the amplified DNA, thereby detecting the nucleic acid.

9. The method of claim 8 , wherein the sample comprises blood, urine, plasma, tissue, isolated cells or fixed cells.

10. The method of claim 8 , wherein the detected nucleic acid indicates the presence of a genetic disease.

11. The method of claim 8 , wherein the detected nucleic acid indicates the presence of an infectious agent in the sample.

12. The method of claim 11 , wherein the infectious agent is a human papilloma virus (HPV), a hepatitis virus, a mycobacterium or a bacterium.

Assignments (1)
CHANGE OF NAME Recorded Jul 20, 2018
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 046599/0855 →
Continuity (5)
Continuation 14925386 · Oct 28, 2015
Continuation 14199753 · Mar 6, 2014
Continuation 12583329 · Aug 18, 2009
Provisional Application 61189800 · Aug 22, 2008
Related Publication 20170226597A1 · Aug 10, 2017
Cited By (5)
US 12,201,699 US 12,286,727 US 12,297,466 US 12,338,436 US 12,529,050